Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Our purpose is to drive bold pursuits in science with a promise to always put patients first.
Check-Cap is developing C-Scan, a novel x-ray imaging capsule that is designed to scan the colon and detect polyps without the need for a cathartic prep. Our aim is to bring a patient friendly system for colon cancer prevention, detecting polyps in the colon, before they become cancerous.
Screening for colon cancer can save lives, and early detection of polyps can prevent cancer. The current adherence to colon cancer screening in the US is approx. 60%, and worldwide, the adherence is substantially lower. This is due to several factors, among which, colon preparation and fear of colonoscopy.
CLASSEEK BIO developed a state-of-the-art, inexpensive, AI-based machine learning toolset for identifying individuals who are at high risk of having colorectal cancer (CRC) in one or two years (as opposed to other methods, e.g., genetic profiling).
Our toolset includes an algorithm that analyses the results of routine conventional blood tests already stored in HMO databases. The algorithm indicates specific individuals at high risk who should be tested by colonoscopy in the near future.
DayTwo is the leading microbiome-based precision medicine company, offering personalized nutrition, diagnostic, and therapeutic solutions using artificial intelligence and machine learning algorithms. DayTwo has the largest full-shotgun DNA sequencing database of the gut microbiome in the world. The database is the foundation for the DayTwo Human Discovery Platform™ to identify precision medicine therapies, diagnostics, and care solutions for metabolic diseases at present, and additional diseases in the future. DayTwo’s initial product enables glycemic control with a Type 2 Diabetes target audience, assisting in balancing blood sugar levels, lowering HbA1C and losing weight using a “food-as-medicine” approach, personalized to the subject’s clinical and personal traits.
ECS-Progastrin, an innovative and ground breaking biotech company specializing in oncology. ECS-Progastrin develops and markets revolutionary solutions based on the detection of hPG80 (Progastrin), a novel ubiquitous cancer blood biomarker. This biomarker is specifically released in the blood by various types of tumors at early stages, making it a highly valuable tool for early detection and cancers monitoring.
Our first two products based on this biomarker; DxPG80.lab for follow-up and DxPG80.smart for early detection, are now commercialized, CE marked and available to the medical community.
These solutions are affordable, simple, reliable and ready to be used by physicians.
Cancer is often detected too late. At Exact Sciences, we work to deliver life-changing innovations in earlier cancer detection to help people make more effective decisions. Alongside our visionary collaborators, and in partnership with communities, we unite the best resources to help advance the fight against cancer, together.
Since 1987, we have become a leading bio-pharmaceutical company with a pioneering portfolio, as well as an expanding pipeline of investigational medicines.
Gilead has helped transform care for people living with HIV with a series of innovative therapies, including the world’s first single tablet regimen for the disease. We continue to discover and develop new treatment and prevention options to help change the course of the HIV epidemic. In addition, we offer a cure for the majority of people living with chronic hepatitis C virus and have treated more than 2 million people around the world with the disease.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.
We are Janssen. We collaborate with the world for the health of everyone in it. Follow us at www.twitter.com/JanssenEMEA. Janssen Research & Development, LLC and Janssen-Cilag International NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Medison is one of the world’s largest commercial partners of leading global biotech companies. Medison is uniquely qualified to provide the complete spectrum of integrated services for biotech companies looking to enter or expand their presence in Israel, Canada and Central East Europe. Medison runs a corporate venture arm with a dedicated research and evaluation team boasting deep scientific and commercial backgrounds. Medison also operates a scouting program to cater its partners and is an active investor in life science projects around drug development and digital health.
As a global leader in medical technology, services, and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic, and economic expertise can help address the complex challenges — such as rising costs, aging populations, and the burden of chronic disease — faced by families and healthcare systems today. But no one can do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes. Taking healthcare Further, Together.
Merck is a vibrant science and technology company that operates across Healthcare, Life Science and Performance Materials. Our nearly 52,000 scientists and employees work in 66 countries to make a positive difference to millions of people’s lives – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for the display and electronic industries. Merck’s Israel biopharma R&D Center, M Ventures’ Bio-Incubator, and collaborations with academia and entrepreneurships in Israel, are all at the forefront of Merck’s march to the future of healthcare – to more joyful and sustainable ways to live.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
Neopharm Israel is one of the leading pharmaceutical companies in Israel, providing the Israeli healthcare market with a wide range of products and integrated services for patients in need with a proven track record of successful market access and launches. Neopharm Israel is the partner-of-choice for multinational pharmaceuticals and biotechnology companies seeking to enter or expand their presence in Israel. For further information on Neopharm Israel please visit: www.neopharmisrael.co.il
Neopharm Israel is part of the Neopharm Group which, through its family of companies, engages in the research and development, manufacturing, marketing, sales and distribution of a broad range of products in the healthcare market in more than 60 countries worldwide. The Neopharm Group operates in three major segments: Pharmaceutical, Consumer Healthcare and Medical Devices, which together generate annual revenues exceeding four hundred million US dollars. The Group has offices in Israel, Europe, United States and employs over 900 employees worldwide. For further information on Neopharm Group please visit: www.neopharmgroup.com
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries, and markets its products in more than 170 countries.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Savicell’s Well-Shield™ is a first-in-class liquid ImmunoBiopsy™ platform that non-invasively measures the metabolic state of the immune system (immunometabolism) and acts as a diagnostic link to early disease states. Savicell demonstrated a compelling cross-validated proof of concept clinical study in lung cancer that was published in Cancer Immunology and Immunotherapy (2018). The 200 subject clinical study yielded 91% sensitivity and 80% specificity in a 20-fold cross-validation. Importantly, results were equally strong in predicting late (III, IV) and early stages (I, II).
VBL Therapeutics, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL’s lead oncology product candidate, ofranergene-obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid-tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in an “all-comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene-obadenovec is currently being studied in a Phase 3 potential-registration trial for platinum-resistant ovarian-cancer.
Vivox supply professional pre-clinical services. Vivox is dedicated to support and promote medical oriented companies to cross their pre-clinical stages for successful FDA, IND application. We are honored to share our pre-clinical services and knowledge both in-vivo and in-vitro with our clients in order to advance potential new therapies towards clinical stages and beyond.
Zion group of companies was established in 2014, developing AIDS and Cancer curing products based on peptides derived from HIV and targeted Lenti-vial particles.
With biological targeting of our products to infected cells or to cancer cells, the death of these cells is promoted specifically, in a safe manner with minimum side effects.
Proprietary basic technologies were developed in the Hebrew University in Jerusalem and were licensed by Zion medical.
With our development team, which consists of the original developers as well as specialists in cell-cultures manipulation with Lenti-viral particles and CMC experts, we can fight these two precarious diseases.